NO20002851L - Blandinger for nasal administrasjon av medikamenter - Google Patents

Blandinger for nasal administrasjon av medikamenter

Info

Publication number
NO20002851L
NO20002851L NO20002851A NO20002851A NO20002851L NO 20002851 L NO20002851 L NO 20002851L NO 20002851 A NO20002851 A NO 20002851A NO 20002851 A NO20002851 A NO 20002851A NO 20002851 L NO20002851 L NO 20002851L
Authority
NO
Norway
Prior art keywords
nasal administration
drugs
compositions
composition
plasma
Prior art date
Application number
NO20002851A
Other languages
English (en)
Other versions
NO329381B1 (no
NO20002851D0 (no
Inventor
Peter Watts
Lisbeth Illum
Original Assignee
West Pharmaceutical Service Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9725519.4A external-priority patent/GB9725519D0/en
Priority claimed from GBGB9805253.3A external-priority patent/GB9805253D0/en
Application filed by West Pharmaceutical Service Dr filed Critical West Pharmaceutical Service Dr
Publication of NO20002851L publication Critical patent/NO20002851L/no
Publication of NO20002851D0 publication Critical patent/NO20002851D0/no
Publication of NO329381B1 publication Critical patent/NO329381B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Blanding for nasal administrasjon av et medikament som er velegnet for å behandle ereksjons problemer hos patte-dyr, hvorved blandingen er tilpasset for å initiere en økning i plasma nivået, etterfulgt av et vedvarende medikament nivå i plasma.
NO20002851A 1997-12-02 2000-06-02 Blandinger for nasal administrasjon for behandling av ereksjonsproblemer eller Parkinsons sykdom NO329381B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9725519.4A GB9725519D0 (en) 1997-12-02 1997-12-02 Nasal formulation
GBGB9805253.3A GB9805253D0 (en) 1998-03-13 1998-03-13 Nasal formulation
PCT/GB1998/003572 WO1999027905A1 (en) 1997-12-02 1998-11-27 Compositions for nasal administration

Publications (3)

Publication Number Publication Date
NO20002851L true NO20002851L (no) 2000-06-02
NO20002851D0 NO20002851D0 (no) 2000-06-02
NO329381B1 NO329381B1 (no) 2010-10-04

Family

ID=26312701

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002851A NO329381B1 (no) 1997-12-02 2000-06-02 Blandinger for nasal administrasjon for behandling av ereksjonsproblemer eller Parkinsons sykdom

Country Status (13)

Country Link
US (2) US6342251B1 (no)
EP (1) EP1035833B1 (no)
JP (2) JP4754067B2 (no)
AR (1) AR017694A1 (no)
AT (1) ATE303131T1 (no)
AU (1) AU751182B2 (no)
CA (1) CA2312839C (no)
DE (1) DE69831421T2 (no)
DK (1) DK1035833T3 (no)
ES (1) ES2249846T3 (no)
NO (1) NO329381B1 (no)
NZ (1) NZ504786A (no)
WO (1) WO1999027905A1 (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
JP2002541100A (ja) * 1999-04-06 2002-12-03 ゾナジェン， インコーポレイテッド ヒトの性的応答を調節するための方法
US6632419B2 (en) * 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
JP2003532640A (ja) 2000-04-07 2003-11-05 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド アポモルヒネ誘導体及びその使用方法
AU2001282373A1 (en) * 2000-05-26 2001-12-03 Horphag Research Limited Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
ES2295391T3 (es) 2001-08-16 2008-04-16 Cmp Therapeutics Limited Microparticulas de quitina y sus usos medicos.
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
WO2003087339A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
AU2003230908A1 (en) * 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
WO2004089374A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
EP1620732A2 (en) * 2003-04-30 2006-02-01 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
WO2006085987A2 (en) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US8846102B2 (en) * 2006-03-30 2014-09-30 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
AU2007241815B2 (en) 2006-04-21 2012-08-16 Toko Yakuhin Kogyo Kabushiki Kaisha Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7976873B2 (en) * 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
WO2009040595A1 (en) * 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
US9433636B2 (en) * 2008-04-24 2016-09-06 Medtronic, Inc. Protective gel based on chitosan and oxidized polysaccharide
WO2009132224A2 (en) 2008-04-24 2009-10-29 Medtronic, Inc. Rehydratable thiolated polysaccharide particles and sponge
AU2009240513B2 (en) 2008-04-24 2015-03-26 Medtronic, Inc. Chitosan-containing protective composition
CN102099060A (zh) 2008-04-24 2011-06-15 麦德托尼克公司 冷电离辐射灭菌
WO2009152374A2 (en) 2008-06-12 2009-12-17 Medtronic Xomed, Inc. Method for treating chronic wounds
US20100086576A1 (en) * 2008-10-06 2010-04-08 Myntti Matthew F Antimicrobial composition and methods of making and using same
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
US10653133B2 (en) 2011-05-10 2020-05-19 Next Science IP Holdings Pty Ltd Antimicrobial solid and methods of making and using same
ES2910361T3 (es) 2013-07-23 2022-05-12 Serenity Pharmaceuticals Llc Composiciones que comprenden desmopresina en combinación con un agonista del receptor adrenérgico beta-3
EP3108245B1 (en) 2014-02-18 2020-07-22 Robert I. Henkin Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
AU2015349811B2 (en) * 2014-11-20 2021-05-06 Acerus Pharmaceuticals USA, LLC Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
EP3056219B1 (fr) * 2015-02-12 2018-08-22 Laboratoires Chemineau Composition à base de plantes de la famille des malvaceae pour une administration sur les muqueuses
FR3032618A1 (fr) * 2015-02-12 2016-08-19 Laboratoires Chemineau Composition a base de plantes de la famille des malvaceae pour une administration dans la cavite nasale
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2023133463A1 (en) * 2022-01-06 2023-07-13 Cyrano Therapeutics, Inc. Improved nasal administration of parkinson's therapeutics

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62123112A (ja) 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
DE3601132A1 (de) 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
JPS62236862A (ja) 1986-04-09 1987-10-16 Nippon Kayaku Co Ltd 人工粘液
EP0296227A1 (en) * 1987-01-08 1988-12-28 Nastech Pharmaceutical Company, Inc. Nasal delivery of amino acids
US4826683A (en) * 1987-01-09 1989-05-02 Bates Harry L Decongestant
FR2614021B1 (fr) * 1987-04-14 1991-03-01 Andre Buzas Derives de la 1-((1,1-diphenyl)-1-alcenyl)-piperazine, procede d'obtention et compositions pharmaceutiques les contenant
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
DE3827561C1 (no) 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
JPH0436233A (ja) * 1990-05-29 1992-02-06 Biomaterial Universe Kk 生理活性物質含有生体内分解吸収性の徐放性製剤
JPH0597706A (ja) 1991-04-09 1993-04-20 Chemex Block Drug Jv アフタ性潰瘍および他の粘膜皮膚障害の処置方法
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
JPH08508472A (ja) * 1993-03-26 1996-09-10 ダブリュー．エイチ．エム． マーカス フランシスカス ジヒドロエルゴタミン、アポモルヒネ及びモルヒネを鼻腔内へ投与するための薬剤
EP0696919B1 (en) * 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
BR9407397A (pt) * 1993-07-12 1996-11-05 Virus Res Inst Vacinas microencapsuladas em hidrogel
JP3696265B2 (ja) * 1994-02-04 2005-09-14 日本オルガノン株式会社 点鼻液剤
DE10199068I2 (de) * 1994-04-22 2004-05-06 Pentech Pharmaceuticals Inc Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces

Also Published As

Publication number Publication date
JP4754067B2 (ja) 2011-08-24
ATE303131T1 (de) 2005-09-15
WO1999027905A1 (en) 1999-06-10
DE69831421D1 (de) 2005-10-06
DE69831421T2 (de) 2006-06-22
EP1035833A1 (en) 2000-09-20
CA2312839C (en) 2008-01-15
AU751182B2 (en) 2002-08-08
NO329381B1 (no) 2010-10-04
NO20002851D0 (no) 2000-06-02
CA2312839A1 (en) 1999-06-10
DK1035833T3 (da) 2006-01-09
AU1253599A (en) 1999-06-16
US6342251B1 (en) 2002-01-29
US20010046519A1 (en) 2001-11-29
NZ504786A (en) 2005-07-29
JP2011026341A (ja) 2011-02-10
EP1035833B1 (en) 2005-08-31
AR017694A1 (es) 2001-09-12
JP2001524509A (ja) 2001-12-04
ES2249846T3 (es) 2006-04-01

Similar Documents

Publication Publication Date Title
NO20002851L (no) Blandinger for nasal administrasjon av medikamenter
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
MXPA03011538A (es) Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
AU2274201A (en) Compounds and compositions for delivering active agents
NZ514574A (en) Novel method of treatment
HUP9803044A2 (hu) Ibuprofentartalmú készítmény
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
AU5906398A (en) Dosage composition for nasal delivery and method of use of the same
EP1247532A4 (en) COMPOSITION PROMOTING THE LACRYMAL SECRETION
NZ535616A (en) Indolymaleimide derivatives as protein kinase c inhibitors
ATE282418T1 (de) Orale verabreichung wirksamer mengen von hyaluronsäure
AU2084801A (en) Antiviral medication
DE69628163D1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
AU3492100A (en) Oxadiazole compounds and compositions for delivering active agents
NO985964L (no) Administrasjonskur for H+, K+ -ATPase-inhibitorer
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
DE69733089D1 (de) Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin
AR012853A1 (es) Formulacion inyectable transparente de compuesto anestesico
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
PA8515601A1 (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos
AR008886A1 (es) Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
PT1150704E (pt) Melagatran para o tratamento da inflamacao
AP1530A (en) Pharmaceutical composition for intramuscular injection containing loxoprofen.
AR014539A1 (es) Derivados de 5'-desoxicitidina, una composicion farmaceutica y kit que los comprende, el uso de los mismos para la fabricacion de un medicamento

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees